PMID- 34292517
OWN - NLM
STAT- MEDLINE
DCOM- 20220429
LR  - 20220531
IS  - 1868-601X (Electronic)
IS  - 1868-4483 (Print)
IS  - 1868-4483 (Linking)
VI  - 13
IP  - 1
DP  - 2022 Feb
TI  - Ligands of the Neuropeptide Y Y2 Receptors as a Potential Multitarget Therapeutic 
      Approach for the Protection of the Neurovascular Unit Against Acute 
      Ischemia/Reperfusion: View from the Perspective of the Laboratory Bench.
PG  - 12-24
LID - 10.1007/s12975-021-00930-4 [doi]
AB  - Ischemic stroke is the third leading cause of death and disability worldwide, 
      with no available satisfactory prevention or treatment approach. The current 
      treatment is limited to the use of "reperfusion methods," i.e., an intravenous or 
      intra-arterial infusion of a fibrinolytic agent, mechanical removal of the clot 
      by thrombectomy, or a combination of both methods. It should be stressed, 
      however, that only approximately 5% of all acute strokes are eligible for 
      fibrinolytic treatment and fewer than 10% for thrombectomy. Despite the 
      tremendous progress in understanding of the pathomechanisms of cerebral ischemia, 
      the promising results of basic research on neuroprotection are not currently 
      transferable to human stroke. A possible explanation for this failure is that 
      experiments on in vivo animal models involve healthy young animals, and the 
      experimental protocols seldom consider the importance of protecting the whole 
      neurovascular unit (NVU), which ensures intracranial homeostasis and is seriously 
      damaged by ischemia/reperfusion. One of the endogenous protective systems 
      activated during ischemia and in neurodegenerative diseases is represented by 
      neuropeptide Y (NPY). It has been demonstrated that activation of NPY Y2 
      receptors (Y2R) by a specific ligand decreases the volume of the postischemic 
      infarction and improves performance in functional tests of rats with arterial 
      hypertension subjected to middle cerebral artery occlusion/reperfusion. This 
      functional improvement suggests the protection of the NVU. In this review, we 
      focus on NPY and discuss the potential, multidirectional protective effects of 
      Y2R agonists against acute focal ischemia/reperfusion injury, with special 
      reference to the NVU.
CI  - (c) 2021. The Author(s).
FAU - Przykaza, Lukasz
AU  - Przykaza L
AD  - Laboratory of Experimental and Clinical Neurosurgery, Mossakowski Medical 
      Research Institute Polish Academy of Sciences, A. Pawinskiego Str. 5, 02-106, 
      Warsaw, Poland.
FAU - Kozniewska, Ewa
AU  - Kozniewska E
AUID- ORCID: 0000-0003-0675-1238
AD  - Laboratory of Experimental and Clinical Neurosurgery, Mossakowski Medical 
      Research Institute Polish Academy of Sciences, A. Pawinskiego Str. 5, 02-106, 
      Warsaw, Poland. ekozniewska@imdik.pan.pl.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210722
PL  - United States
TA  - Transl Stroke Res
JT  - Translational stroke research
JID - 101517297
RN  - 0 (Ligands)
RN  - 0 (Neuropeptide Y)
SB  - IM
MH  - Animals
MH  - *Brain Ischemia/drug therapy
MH  - Humans
MH  - Infarction, Middle Cerebral Artery/drug therapy
MH  - Ischemia
MH  - Ligands
MH  - Neuropeptide Y/pharmacology/therapeutic use
MH  - Rats
MH  - Reperfusion
MH  - *Stroke
PMC - PMC8766383
OTO - NOTNLM
OT  - Cerebral ischemia/reperfusion
OT  - Neuropeptide Y Y2 receptors
OT  - Neuroprotection
OT  - Neurovascular unit
OT  - Stroke therapy
COIS- The authors declare that they have no conflict of interest
EDAT- 2021/07/23 06:00
MHDA- 2022/04/30 06:00
PMCR- 2021/07/22
CRDT- 2021/07/22 12:34
PHST- 2020/11/18 00:00 [received]
PHST- 2021/07/12 00:00 [accepted]
PHST- 2021/07/11 00:00 [revised]
PHST- 2021/07/23 06:00 [pubmed]
PHST- 2022/04/30 06:00 [medline]
PHST- 2021/07/22 12:34 [entrez]
PHST- 2021/07/22 00:00 [pmc-release]
AID - 10.1007/s12975-021-00930-4 [pii]
AID - 930 [pii]
AID - 10.1007/s12975-021-00930-4 [doi]
PST - ppublish
SO  - Transl Stroke Res. 2022 Feb;13(1):12-24. doi: 10.1007/s12975-021-00930-4. Epub 
      2021 Jul 22.